Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

Jessica C. L. Notohardjo*, Malou C. P. Kuppen, Hans M. Westgeest, Reindert J. A. van Moorselaar, Niven Mehra, Jules L. L. M. Coenen, Inge M. van Oort, Aad de Vos, Walter L. Vervenne, Alphons C. M. van den Bergh, Katja K. H. Aben, Diederik M. Somford, Andries M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen, Alfons J. M. van den Eertwegh

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

2 Citaten (Scopus)
27 Downloads (Pure)


Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive

Originele taal-2English
Pagina's (van-tot)788-796
Aantal pagina's9
TijdschriftEuropean Urology Focus
Nummer van het tijdschrift4
StatusPublished - jul.-2021

Citeer dit